1477 Overzicht aandelen Ocumension Therapeutics is, samen met haar dochterondernemingen, actief als een oftalmologisch farmaceutisch platformbedrijf in de Volksrepubliek China. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
Ocumension Therapeutics Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Ocumension Therapeutics Historische aandelenkoersen Huidige aandelenkoers HK$4.41 52 Week Hoogtepunt HK$7.54 52 Week Laag HK$4.13 Bèta 0.80 1 maand verandering -20.68% 3 maanden verandering -17.26% 1 Jaar Verandering -34.67% 3 jaar verandering -73.75% 5 jaar verandering n/a Verandering sinds IPO -88.08%
Recent nieuws en updates
Ocumension Therapeutics Announces Patient Enrollment Completed in the Second Phase III Clinical Trial of OT-301 in China Dec 03
Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director Oct 21
New minor risk - Shareholder dilution Oct 20
Ocumension Therapeutics Announces New Drug Application of OT-502 Accepted by the National Medical Products Administration Sep 24
With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For Sep 21
Ocumension Therapeutics Announces New Drug Application of OT-1001 Approved by the National Medical Products Administration Sep 19 Meer updates bekijken
Ocumension Therapeutics Announces Patient Enrollment Completed in the Second Phase III Clinical Trial of OT-301 in China Dec 03
Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director Oct 21
New minor risk - Shareholder dilution Oct 20
Ocumension Therapeutics Announces New Drug Application of OT-502 Accepted by the National Medical Products Administration Sep 24
With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For Sep 21
Ocumension Therapeutics Announces New Drug Application of OT-1001 Approved by the National Medical Products Administration Sep 19
Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results Aug 15
New minor risk - Profitability Aug 15
First half 2024 earnings released: CN¥0.23 loss per share (vs CN¥0.32 loss in 1H 2023) Aug 14
Ocumension Therapeutics to Report First Half, 2024 Results on Aug 12, 2024 Jul 30
Ocumension Therapeutics Announces Biologic License Application for OT-702 Accepted by the National Medical Products Administration Jul 17
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now Jun 13
Ocumension Therapeutics, Annual General Meeting, Jun 20, 2024 May 25
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 30
Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable Apr 29
Consensus revenue estimates decrease by 14%, EPS upgraded Mar 28
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 23
Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202 Mar 14
Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation Mar 14
Ocumension Therapeutics to Report Fiscal Year 2023 Results on Mar 21, 2024 Mar 08 Ocumension Therapeutics (SEHK:1477) commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023. Dec 14
Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China Nov 30
Ocumension Therapeutics Completes Patient Enrollment in the Phase II Clinical Trial of OT-202 in China Nov 23
Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023 Oct 01
Consensus revenue estimates decrease by 13% Sep 12
Consensus revenue estimates fall by 27% Aug 31
Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates Aug 29
New minor risk - Profitability Aug 28
First half 2023 earnings released: CN¥0.32 loss per share (vs CN¥0.31 loss in 1H 2022) Aug 26
Ocumension Therapeutics to Report First Half, 2023 Results on Aug 24, 2023 Aug 15
Ocumension Therapeutics Announces Clinical Trial Authorization for Initiating A Phase III Clinical Trial of Ot-101-S Jul 23
We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely Jul 13
Forecast to breakeven in 2025 Jul 07
Ocumension Therapeutics Completes Patient Enrollment in Globalmulti-Center Phase III Clinical Trial of OT-101 Jun 02
Consensus EPS estimates fall by 24% Apr 06
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 31
Ocumension Therapeutics Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended December 31, 2022 Feb 15
No longer forecast to breakeven Feb 07
Ocumension Therapeutics Provides Update on Phase I Clinical Trial of Ot-202 Feb 04
Ocumension Therapeutics Announces Patient Enrollment Complete in the Phase III Clinical Trial of OT-101 in China Feb 02
Now 22% undervalued Jan 30
Now 22% undervalued after recent price drop Jan 12
Less than half of directors are independent Nov 16
Board Member exercised options and sold HK$558k worth of stock Sep 25
Consensus forecasts updated Sep 02
First half 2022 earnings released: CN¥0.31 loss per share (vs CN¥0.12 loss in 1H 2021) Aug 29
Ocumension Therapeutics to Report First Half, 2022 Results on Aug 26, 2022 Aug 17
Board Member recently sold HK$246k worth of stock Jul 24
Now 24% undervalued Jul 12
Ocumension Therapeutics Receives Approval from the National Medical Products Administration for Yutio Chronic Non-Infectious Uveitis Jun 24
EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ(R) for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye Jun 22
Ocumension Therapeutics Announces Executive Changes Jun 16
Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-703 in China Jun 10
Ocumension Therapeutics Receives Approval from the National Medical Products Administration for its IND Application to Begin the Phase Iii Clinical Study for Fluocinolone Acetonide Intravitreal Implant Jun 09
Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount? Jun 02
Less than half of directors are independent Apr 27
Ocumension Therapeutics Appoints Mr. Zhenyu Zhang as Independent Non-Executive Director, the Chairman of the Remuneration Committee and a Member of the Nomination Committee and Audit Committee Apr 09
Ocumension Therapeutics Announces Demise of Lianming HE, Independent Non-Executive Director, Chairman of the Remuneration Committee and Member of the Audit Committee and Nomination Committee Apr 01
Consensus forecasts updated Apr 01
Forecast to breakeven in 2024 Mar 30
Full year 2021 earnings: EPS and revenues miss analyst expectations Mar 28
Consensus forecasts updated Mar 17
Ocumension Therapeutics Voluntary Announcement primary Clinical Endpoint Achieved in the Phase III clinical Trial of OT-1001 Mar 04
Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China Mar 03
We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate Jan 20
Ocumension Therapeutics Announces First Patient Enrolled in the Clinical Trial of self-Developed Class I New Drug OT-202 in China Jan 05
Consensus forecasts updated Dec 18
We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate Sep 27
First half 2021 earnings released: CN¥0.12 loss per share (vs CN¥27.36 loss in 1H 2020) Sep 24
Ocumension Therapeutics Receives CDE Approval for Commencement of a Phase III Clinical Trial OT-502 (DEXYCU®) in China Sep 15
First half 2021 earnings released: CN¥0.12 loss per share (vs CN¥27.36 loss in 1H 2020) Aug 23
Ocumension Therapeutics MHRA Approval Received for Phase III Clinical Trial of OT-101 in the United Kingdom Aug 04
Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-101 Jul 15
Ocumension Therapeutics Announces Clinical Trial Authorization for Initiatinga Phase III Clinical Trial of OT-101 Accepted in United Kingdom May 21
Ocumension Therapeutics Announces Investigational New Drug Application for Initiating A Multi-Regional Phase Iii Clinical Trial in the People's Republic of China for OT-101 May 12
Non-Executive Director has left the company Mar 24
Ocumension Therapeutics Announces Board Changes Mar 21
Ocumension Therapeutics, Annual General Meeting, Jun 29, 2021 Mar 20
New 90-day low: HK$22.50 Mar 10
Ocumension Therapeutics to Report Fiscal Year 2020 Results on Mar 19, 2021 Mar 10
Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Denali Phase 3 Trial Mar 05
Ocumension Therapeutics Announces Second Phase III Clinical Trial of OT-301 Approved in China Mar 04
Ocumension Therapeutics Announces Investigational New Drug Approval for Initiating A Multi-Regional Phase III Clinical Trial Feb 23
Ocumension Therapeutics Announces Phase III Clinical Trial of the Recently In-Licensed Drug Candidate of the Group Feb 10
Ocumension Therapeutics has completed a Follow-on Equity Offering in the amount of HKD 1.5876 billion. Jan 24
Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful? Jan 23
Ocumension Therapeutics announced that it expects to receive HKD 793.8 million in funding from 6 Dimensions Capital, L.P. Jan 14
New 90-day high: HK$29.70 Jan 11 Ocumension Therapeutics Announces First Patient Enrolled in the Phase III Clinical Trial of OT-1001 (Zerviate) in China
New 90-day high: HK$26.75 Dec 17
Ocumension Therapeutics Initiates the Real World Study of Its Core Product, OT-401 (YUTIQ) in Boao Super Hospital in Hainan Province, China Dec 02
Ocumension Therapeutics Receives Approval by Chinese Authorities for Local Start of Mont Blanc Phase 3 Trial Oct 27
New 90-day low: HK$22.30 Oct 22
Ocumension Therapeutics Receives Approval from China’S Center for Drug Evaluation of the National Medical Products Administration Sep 22
Ocumension Therapeutics to Report First Half, 2020 Results on Aug 26, 2020 Aug 18 Rendement voor aandeelhouders 1477 HK Pharmaceuticals HK Markt 7D -5.0% 0.2% 1.5% 1Y -34.7% -3.7% 20.6%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: 1477 presteerde slechter dan de Hong Kong Pharmaceuticals -sector, die het afgelopen jaar een rendement van -3.7 % opleverde.
Rendement versus markt: 1477 presteerde slechter dan Hong Kong Market , dat het afgelopen jaar een rendement van 20.6 % opleverde.
Prijsvolatiliteit Is 1477's price volatile compared to industry and market? 1477 volatility 1477 Average Weekly Movement 8.6% Pharmaceuticals Industry Average Movement 6.4% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.0%
Stabiele aandelenkoers: 1477 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van 1477 is het afgelopen jaar stabiel geweest.
Over het bedrijf Ocumension Therapeutics is, samen met haar dochterondernemingen, actief als een oftalmologisch farmaceutisch platformbedrijf in de Volksrepubliek China. Het ontdekt, ontwikkelt en commercialiseert therapieën voor oogheelkundige patiënten. Het portfolio omvat producten en geneesmiddelen voor de behandeling van chronische niet-infectieuze uveïtis, blefaritis, infectieuze en allergische conjunctivitis, diabetisch maculair oedeem, droge ogen, glaucoom en oculaire hypertensie, postoperatieve ontsteking, choroïdale neovascularisatie, bacteriële conjunctivitis, retinitis pigmentosa, acuut glaucoom, leeftijdsgebonden maculadegeneratie, cornea afstoting, bijziendheid en optische neuritis.
Meer tonen Ocumension Therapeutics Samenvatting Hoe verhouden de winst en inkomsten van Ocumension Therapeutics zich tot de beurswaarde? 1477 fundamentele statistieken Marktkapitalisatie HK$3.60b Inkomsten(TTM ) -HK$343.47m Inkomsten(TTM ) HK$330.23m
10.9x P/S-verhouding
-10.5x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) 1477 resultatenrekening (TTM ) Inkomsten CN¥310.29m Kosten van inkomsten CN¥129.44m Brutowinst CN¥180.86m Overige uitgaven CN¥503.58m Inkomsten -CN¥322.73m
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) -0.40 Brutomarge 58.29% Nettowinstmarge -104.01% Schuld/Eigen Vermogen Verhouding 0%
Hoe presteerde 1477 op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2024/12/25 05:13 Aandelenkoers aan het einde van de dag 2024/12/24 00:00 Inkomsten 2024/06/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten Ocumension Therapeutics wordt gevolgd door 6 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Yanyin Zhu China International Capital Corporation Limited Fang Quan China International Capital Corporation Limited Ziyi Chen Goldman Sachs
Toon 3 meer analisten 
